New combo therapy aims to boost survival in adult leukemia

NCT ID NCT07495631

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve higher rates of remission and longer survival. Participants will go through several phases of treatment over many months, with the option to add immunotherapy based on their preference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

A combination of chemotherapy drugs (vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, methotrexate), venetoclax, and immunotherapy (inotuzumab ozogamicin, blinatumomab)

What this could lead to

If successful, this approach could improve remission rates and long-term survival for adults with a hard-to-treat leukemia, potentially offering a more effective treatment option.

What could go wrong

This is a small, early-phase study with only 43 participants, so results may not apply to everyone. The intense chemotherapy and immunotherapy can cause serious side effects like infections and organ damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia adult acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Blood Diseases Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

    Contact